Merck claims another late-stage win for oral cholesterol drugnews2025-09-02T16:41:53+00:00September 2nd, 2025|Endpoints News|
Amgen to expand California headquarters with new $600M R&D center news2025-09-02T16:19:01+00:00September 2nd, 2025|Endpoints News|
Upstream Bio’s Phase 2 win could set it up as a potential Dupixent, Tezspire competitornews2025-09-02T15:17:06+00:00September 2nd, 2025|Endpoints News|
Ionis says ‘unprecedented’ data support Tryngolza’s label expansion in severe triglyceride diseasenews2025-09-02T11:00:26+00:00September 2nd, 2025|Endpoints News|
#ESC25: Novartis’ Leqvio cuts lipid levels, muscle pain in high-risk cholesterol patientsnews2025-08-30T15:00:23+00:00August 30th, 2025|Endpoints News|
#ESC25: Ionis’ study success in moderately high triglyceride levels raises the curtain for pivotal readout in severe diseasenews2025-08-30T14:45:51+00:00August 30th, 2025|Endpoints News|
#ESC25: AstraZeneca aims for 2025 filing with ‘best-in-class’ hypertension pillnews2025-08-30T14:15:52+00:00August 30th, 2025|Endpoints News|
#ESC25: Cytokinetics says heart drug data could change standard of carenews2025-08-30T07:18:35+00:00August 30th, 2025|Endpoints News|
FDA approves BTK inhibitor that’s key to Sanofi’s immunology strategynews2025-08-29T22:01:01+00:00August 29th, 2025|Endpoints News|
FDA approves Eisai and Biogen’s subcutaneous Leqembinews2025-08-29T21:00:40+00:00August 29th, 2025|Endpoints News|
